Arrevus Inc.
Quick facts
Phase 2 pipeline
- ARV-1801 · Oncology
ARV-1801 is a bispecific antibody that simultaneously engages T cells and tumor cells to redirect immune attack against cancer. - Ceftazidime or meropenem · Infectious disease
Ceftazidime and meropenem are broad-spectrum cephalosporin antibiotics that inhibit bacterial cell wall synthesis.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Related
- Sector hub: All tracked pharma companies